Complications of β-thalassemia major in North America
The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
Treatment of patients with β-thalassemia major has improved dramatically during the past 40 years; however, the current clinical status of these patients remains poorly characterized. We performed a cross-sectional study of 342 patients in the Registry of the National Institutes of Health-sponsored Thalassemia Clinical Research Network. Evidence of hepatitis C exposure was present in 35% of tested patients, was associated with age, and had a rate of spontaneous viral clearance of 33%. Ferritin levels ranged from 147 to 11 010 ng/mL (median, 1696 ng/mL). Median hepatic iron content was 7.8 mg/g dry weight and 23% of patients had values of 15 mg/g dry weight or higher. No patients 15 years or younger and 5% of patients aged 16 to 24 years had heart disease requiring medication. Ten percent had cirrhosis on biopsy. Endocrinologic complications were common among adults. Seventy-four (22%) patients had recent implantable central venous access devices (CVADs) placed. Among 80 episodes of bacteremia in 38 patients, 90% were attributable to the CVAD. Among 330 patients who had received deferoxamine chelation therapy, 224 (68%) reported no complications. We conclude that hepatitis C, iron-related organ dysfunction, and complications of iron chelation therapy are strongly age-dependent in North American patients with β-thalassemia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Iron-Chelating Therapy and the Treatment of Thalassemia
Olivieri, N. F., & Brittenham, G. M. (1997) · Blood · doi:10.1182/blood.v89.3.739 · Cited by 1,089
Pathogenesis, Natural History, Treatment, and Prevention of Hepatitis C
Liang, T. J., Rehermann, B., Seeff, L. B., & Hoofnagle, J. H. (2000) · Annals of Internal Medicine · doi:10.7326/0003-4819-132-4-200002150-00008 · Cited by 868
Survival in Medically Treated Patients with Homozygous β-Thalassemia
Olivieri, N. F., Nathan, D. G., MacMillan, J. H., Wayne, A. S., Liu, P. P., McGee, A., Martin, M., Koren, G., & Cohen, A. R. (1994) · New England Journal of Medicine · doi:10.1056/nejm199409013310903 · Cited by 852
Self-citationBrittenham, G. M., Griffith, P. M., Nienhuis, A. W., McLaren, C. E., Young, N. S., Tucker, E. E., Allen, C. J., Farrell, D. E., & Harris, J. W. (1994) · New England Journal of Medicine · doi:10.1056/nejm199409013310902 · Cited by 829
(1973) · Medical Journal of Australia · doi:10.5694/j.1326-5377.1973.tb111034.x · Cited by 811
Olivieri, N. F. (1999) · New England Journal of Medicine · doi:10.1056/nejm199907083410207 · Cited by 728
Results of Long-Term Iron-Chelating Therapy
Gabutti, V., & Piga, A. (2009) · Acta Haematologica · doi:10.1159/000203853 · Cited by 378
Survival and Disease Complications in Thalassemia Major
BORGNA‐PIGNATTI, C., RUGOLOTTO, S., DE STEFANO, P., PIGA, A., DI GREGORIO, F., GAMBERINI, M. R., SABATO, V., MELEVENDI, C., CAPPELLINI, M. D., & VERLATO, G. (1998) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1998.tb10479.x · Cited by 343
Davis, B. A., & Porter, J. B. (2000) · Blood · doi:10.1182/blood.v95.4.1229.004k32_1229_1236 · Cited by 279
Transfusion-Transmitted Malaria in the United States from 1963 through 1999
Mungai, M., Tegtmeier, G., Chamberland, M., & Parise, M. (2001) · New England Journal of Medicine · doi:10.1056/nejm200106283442603 · Cited by 275
Pathophysiology of Iron Overloada
HERSHKO, C., LINK, G., & CABANTCHIK, I. (1998) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1998.tb10475.x · Cited by 248
High prevalence of low bone mass in thalassaemia major
Jensen, Tuck, Agnew, Koneru, Morris, Yardumian, Prescott, Hoffbrand, & Wonke (1998) · British Journal of Haematology · doi:10.1046/j.1365-2141.1998.01108.x · Cited by 177
Association between HLA class II genotype and spontaneous clearance of hepatitis C viraemia
Cramp, M. E., Carucci, P., Underhill, J., Naoumov, N. V., Williams, R., & Donaldson, P. T. (1998) · Journal of Hepatology · doi:10.1016/s0168-8278(98)80005-6 · Cited by 161
Iron Chelators for Thalassaemia
Hershko, C., Konijn, A. M., & Link, G. (1998) · British Journal of Haematology · doi:10.1046/j.1365-2141.1998.00726.x · Cited by 160
BONE DISEASE IN β‐THALASSAEMIA MAJOR
Wonke (1998) · British Journal of Haematology · doi:10.1046/j.1365-2141.1998.01107.x · Cited by 98
A Risk-Benefit Assessment of Iron-Chelation Therapy
Porter, J. B. (1997) · Drug Safety · doi:10.2165/00002018-199717060-00006 · Cited by 95
Cirrhosis associated with multiple transfusions in thalassaemia.
Jean, G., Terzoli, S., Mauri, R., et al. (1984) · Archives of Disease in Childhood · doi:10.1136/adc.59.1.67 · Cited by 69
Telfer, P. T., Garson, J. A., Whitby, K., Grant, P. R., Yardumian, A., Hoffbrand, A. V., & Wonke, B. (1997) · British Journal of Haematology · doi:10.1046/j.1365-2141.1997.2953112.x · Cited by 62
Growth, Puberty and Endocrine Function in Beta-Thalassaemia Major
Low, L. C. K. (1997) · Journal of Pediatric Endocrinology and Metabolism · doi:10.1515/jpem.1997.10.2.175 · Cited by 61
Elfer, P. T. T., Arson, J. A. G., Hitby, K. W., Rant, P. R. G., Ardumian, A. Y., Offbrand, A. V. H., & Onke, B. W. (1997) · Cited by 52
Weatherall, D. J., & Clegg, J. B. (2001) · Wiley eBooks · doi:10.1002/9780470696705.ch15 · Cited by 32
Cited by
Galanello, R., & Origa, R. (2010) · Orphanet Journal of Rare Diseases · doi:10.1186/1750-1172-5-11 · Cited by 1,466
Rund, D., & Rachmilewitz, E. (2005) · New England Journal of Medicine · doi:10.1056/nejmra050436 · Cited by 939
Hepcidin in iron overload disorders
Papanikolaou, G., Tzilianos, M., Christakis, J. I., Bogdanos, D., Tsimirika, K., MacFarlane, J., Goldberg, Y. P., Sakellaropoulos, N., Ganz, T., & Nemeth, E. (2005) · Blood · doi:10.1182/blood-2004-12-4844 · Cited by 445
Rachmilewitz, E. A., & Giardina, P. J. (2011) · Blood · doi:10.1182/blood-2010-08-300335 · Cited by 417
Pennell, D. J., Udelson, J. E., Arai, A. E., Bozkurt, B., Cohen, A. R., Galanello, R., Hoffman, T. M., Kiernan, M. S., Lerakis, S., Piga, A., et al. (2013) · Circulation · doi:10.1161/cir.0b013e31829b2be6 · Cited by 394
Self-citation
Metadata
- Authors
- Cunningham, M. J., Macklin, E. A., Neufeld, E. J., Cohen, A. R., & the Thalassemia Clinical Research Network
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2004-07-01
- Volume
- 104
- Issue
- 1
- Pages
- 34-39
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W2015578999
- Cited by
- 454
- References
- 21
- FWCI
- 10.85
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.